Optimization and it's influence on value of doses in HDR and PDR brachytherapy

Neoplasma

Volumn 57, Issue 4, 2010, Pages 369-376

  Skowronek, J ^a   Zwierzchowski, G ^a   Piotrowski, T ^a   Milecki, P ^a  

^a GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

BED; HDR brachytherapy; Healthy tissues; Optimization; PDR brachytherapy

Indexed keywords

ADULT; AGED; ARTICLE; BIOLOGICALLY EQUIVALENT DOSE; BRACHYTHERAPY; BRAIN TUMOR; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; FEMALE; HEAD AND NECK CANCER; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS CANCER; PROCESS OPTIMIZATION; PULSED DOSE RATE BRACHYTHERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RECTUM CANCER; RISK ASSESSMENT; SARCOMA; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; NEOPLASM; RADIATION RESPONSE; RELATIVE BIOLOGIC EFFECTIVENESS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955289336     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_04_369     Document Type: Article

References (49)

1. MAZERON JJ, BOISSERIE G, BAILLET F. [Pulse dose rate curietherapy] Bull Cancer Radiother 1995; 82: 332-335.
2. SKOWRONEK J. Comparison of effectiveness and risk of complications after Pulsed-Dose-Rate Brachytherapy and High-Dose-Rate Brachytherapy using Biologically Effective Dose model. Rep Pract Oncol Radioth 2005; 10: Suppl 1.
3. SKOWRONEK J, ZWIERZCHOWSKI G, PIOTROWSKI T. Hyperfractionation of HDR brachytherapy-influence on Dose and Biologically Equivalent Dose in Clinical Target Volume and healthy tissues. J Contemp Brachyther 2009; 1, 2: 109-116.
4. SMINIA P, SCHNEIDER CJ. From continuous low dose rate brachytherapy to pulsed brachytherapy. Exp Strahlenther Klin Strahlenbiol 1996; 5: 146-147.
5. POLO A. Pulsed dose rate brachytherapy. Clin Transl Oncol 2008; 10(6): 324-333. doi:10.1007/s12094-008-0208-7
6. CHARGARI C, MAGNÉ N, DUMAS I, MESSAI T, VICENZI L et al. Physics contributions and clinical outcome with 3DMRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 2009; 74(1): 133-139. doi:10.1016/j.ijrobp.2008.06.1912
7. BRENNER DJ, HALL EJ, HUANG Y, SACHS RK. Potential reduced late effects for pulsed brachytherapy compared with conventional LDR. Int J Radiat Oncol Biol Phys 1995; 31: 201-202. doi:10.1016/0360-3016(95)92198-9
8. CHEN CZ, HUANG Y, HALL EJ, BRENNER DJ. Pulsed brachytherapy as a substitute for continuous low dose rate: an in vitro study with human carcinoma cells. Int J Radiat Oncol Biol Phys 1997; 37: 137-43. doi:10.1016/S0360-3016(96)00461-0
9. HALL EJ, BRENNER DJ. Pulsed dose rate brachytherapy: can we take advantage of new technology? Int J Radiat Oncol Biol Phys 1996; 34: 511-512. doi:10.1016/0360-3016(95)02195-7
10. The GEC ESTRO Handbook of Brachytherapy. Gerbaulet A, Potter R, Mazeron J-J, Meertens H, Van Limbergen E (eds). ESTRO; Bruksela 2002.
11. JACOB D, RABEN A, SARKAR A, GRIMM J, SIMPSON L. Anatomy-based inverse planning simulated annealing optimization in high-dose-rate prostate brachytherapy: significant dosimetric advantage over other optimization techniques. Int J Radiat Oncol Biol Phys 2008; 72(3): 820-827. doi:10.1016/ j.ijrobp.2008.02.009
12. LINDEGAARD JC, TANDERUP K, NIELSEN SK, HAACK S, GELINECK J. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2008; 71(3): 756-764.
13. BERNARD S, RENIERS B, SCALLIET P, VYNCKIER S. Optimization of a breast implant in Brachytherapy PDR: validation with Monte Carlo simulation and measurements with TLDs and GafChromic films. Radiother Oncol 2005; 76(3): 326-333. doi:10.1016/j.radonc.2005.04.016
14. PALAZZONI G, NARDONE L, CIANCIULLI M, CIRESA M, AUSILI-CEFARO G. Dose fractionation and biological optimization in breast cancer. Rays 2004; 29(3): 333-338.
15. PEREZ CA. Dose fractionation and biological optimization in carcinoma of the uterine cervix. Rays 2004; 29(3): 253-270.
16. AHMAD F, ALETTI P, CHARRA-BRUNAUD C, VAN DER LAARSE R, LAPEYRE M et al. Influence of dose point and inverse optimization on interstitial cervical and oropharyngeal carcinoma brachytherapy. Radiother Oncol 2004; 73(3): 331-337. doi:10.1016/j.radonc.2004.10.008
17. PIETERS BR, VAN DE KAMER JB, VAN HERTEN YR, VAN WIERINGEN N, D'OLIESLAGER GM et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008; 88(1): 46-52. doi:10.1016/j.radonc.2008.02.023
18. BRENNER DJ, HALL EJ. Conditions for the equivalence of continuous to pulsed dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1991; 20: 180-190. doi:10.1016/0360-3016(91)90158-Z
19. FOWLER JF, MOUNT M. Pulsed brachytherapy: the conditions for no significant loss of therapeutic ratio compared with traditional low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1992; 23: 661-669. doi:10.1016/0360-3016(92)90026-E
20. FOWLER JF, VAN LIMBERGEN EF. Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues. Int J Radiat Oncol Biol Phys 1997; 37: 877-883. doi:10.1016/S0360-3016(96)00565-2
21. BRENNER DJ. Radiation biology in brachytherapy. J Surg Oncol 1997; 65: 66-70. doi:10.1002/(SICI)1096-9098(199705)65:1<66:: AID-JSO13>3.0.CO;2-Q
22. MILLAR WT, HENDRY JH, CANNEY PA. The influence of the number of fractions and bi-exponential repair kinetics on biological equivalence in pulsed brachytherapy. Br J Radiol 1996; 69: 457-468. doi:10.1259/0007-1285-69-821-457
23. POP LA, MILLAR WT, VISSER AG, VAN DER KOGEL AJ. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 215-226. doi:10.1016/S0360-3016(01)01543-7
24. BRENNER DJ, HALL EJ, RANDERS-PEHRSON G, HUANG Y, JOHNSON GW et al. Quantitative comparisons of continuous and pulsed low dose rate regimens in a model late-effect system. Int J Radiat Oncol Biol Phys 1996; 34: 905-910. doi:10.1016/0360-3016(95)02182-5
25. BRENNER DJ, SCHIFF PB, HUANG Y, HALL EJ. Pulseddose-rate brachytherapy: design of convenient (daytime-only) schedules. Int J Radiat Oncol Biol Phys 1997; 39: 809-815. doi:10.1016/S0360-3016(97)00097-7
26. VISSER AG, VAN DEN AARDWEG GJMJ, LEVENDAG PC. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments. Int J Radiat Oncol Biol Phys 1996; 34: 497-505. doi:10.1016/0360-3016(95)02054-3
27. STEEL GORDON G. Basic Clinical Radiobiology. Edward Arnold; London 1993: 72-79.
28. MOULD RF, BATTERMANN JJ, MARTINEZ AA, SPEISER BL. Brachytherapy-from Radium to Optimization. Nucletron B.V. 1994.
29. BARENDSEN GW. Dose fractionation, dose rate, and isoeffect relationship for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981-1997. doi:10.1016/0360-3016(82)90459-X
30. DE PREE CH, POPOWSKI Y, WEBER D, NOUET PH, ROUZAUD M et al. Feasibility and tolerance of pulsed dose rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 1999; 43: 971-976. doi:10.1016/S0360-3016(98)00525-2
31. FOWLER JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679-694. doi:10.1259/0007-1285-62-740-679
32. MACIEJEWSKI B. Tolerancja zdrowych tkanek w radioterapii nowotworów. Odczyny popromienne. Centrum Onkologii Instytutu im. Marii Skłodowskiej-Curie, Gliwice 1991 [Polish].
33. DALE RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-528. doi:10.1259/0007-1285-58-690-515
34. THAMES HD, HENDRY JH. Fractionation in Radiotherapy. Taylor and Francis; London 1987.
35. PEIFFERT D, CASTELAIN B, THOMAS L, ARDIET JM, BAILLET F et al. Pulse dose rate brachytherapy in head and neck cancers. Feasibility study of a French cooperative group. Radiother Oncol 2001; 58: 71-75. doi:10.1016/S0167-8140(00)00294-2
36. BÖLLING T, MOUSTAKIS C, ELSAYED H, MÜLLER SB, WEINING C et al. Rectum dose reduction and individual treatment plan optimization for high-dose-rate prostate brachytherapy. Brachytherapy 2007; 6(4): 280-285. doi:10.1016/j.brachy.2007.06.001
37. CHAJON E, DUMAS I, TOULEIMAT M, MAGNÉ N, COULOT J et al. Inverse planning approach for 3-D MRIbased pulse-dose rate intracavitary brachytherapy in cervix cancer. Int J Radiat Oncol Biol Phys 2007; 69(3): 955-961. doi:10.1016/j.ijrobp.2007.07.2321
38. SKOWRONEK J, PIOTROWSKI T, ZWIERZCHOWSKI G. PDR brachytherapy-describing of a method and a review of clinical applications, Rep Pract Oncol Radioth 2001; 4: 197-202.
39. LEVENDAG PC, SCHMITZ PI, JANSEN PP, SENAN S, EIJKENBOOM WMH et al. Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate. Int J Radiat Oncol Biol Phys 1997; 38: 497-506. doi:10.1016/ S0360-3016(97)00046-1
40. SKOWRONEK J, ADAMSKA K, ZWIERZCHOWSKI G, LIEBERT W. Pulsed Dose Rate and High Dose Rate Brachytherapy in treatment of malignant glioma recurrences-preliminary assessment, Sectio D (Medicina) Annales UMCS 2001, VIII Suplement, 189-198.
41. TEYMOURNIA L, BERGER D, KAUER-DORNER D, POLJANC K, SEITZ W et al. Comparison of PDR brachytherapy and external beam radiation therapy in the case of breast cancer. Phys Med Biol 2009; 54(8): 2585-2595. doi:10.1088/ 0031-9155/54/8/022
42. JOHANSSON B, KARLSSON L, LILJEGREN G, HARDELL L, PERSLIDEN J. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study. Radiother Oncol 2009; 90(1): 30-35. doi:10.1016/ j.radonc.2008.02.022
43. ZIEMLEWSKI A, ZIENKIEWICZ J, SERKIES K, BADZIO A. Preliminary report of pulsed dose rate brachytherapy in headand-neck cancer. Strahlenther Onkol 2007; 183(9): 512-516. doi:10.1007/s00066-007-1685-2
44. OTT OJ, LOTTER M, SAUER R, STRNAD V. Accelerated partial-breast irradiation with interstitial implants: the clinical relevance of the calculation of skin doses. Strahlenther Onkol 2007; 183(8): 426-31. doi:10.1007/s00066-007-1738-6
45. MELZNER WJ, LOTTER M, SAUER R, STRNAD V. Quality of interstitial PDR-brachytherapy-implants of headand-neck-cancers: predictive factors for local control and late toxicity? Radiother Oncol 2007; 82(2): 167-173. doi:10.1016/ j.radonc.2006.12.004
46. STRNAD V, MELZNER W, GEIGER M, ZENK J, WALDFAHRER F et al. Role of interstitial PDR brachytherapy in the treatment of oral and oropharyngeal cancer. A single-institute experience of 236 patients. Strahlenther Onkol 2005; 181(12): 762-767. doi:10.1007/s00066-005-1424-5
47. BRENNER DJ, HALL EJ. Fractionated high dose rate versus low dose rate regimens for intracavitary technique of the cervix. Br J Radiol 1991; 64: 133-41. doi:10.1259/0007-1285-64-758-133
48. POP LA, VAN DEN BROEK JF, VISSER AG, VAN DER KOGEL AJ. Constraints in the use of repair half times and mathematical modelling for the clinical application of HDR and PDR treatment schedules as an alternative for LDR brachytherapy. Radiother Oncol 1996; 38: 153-162. doi:10.1016/0167-8140(95)01695-3
49. TURESSON I. Radiobiological aspects of continuous lowdose-rate irradiation and fractionated high¬ dose rate irradiation. Radiother Oncol 1990; 19: 1-16. doi:10.1016/ 0167-8140(90)90161-O14 Furdova